Navigation Links
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Date:10/29/2009

CRANBURY, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the third quarter 2009. Additionally, Amicus also today announced that it has reacquired all global development and commercialization rights from its partner, Shire, for its lead lysosomal storage disease programs as a result of the parties' mutual termination of their collaboration. The Company also announced a workforce reduction of approximately 20 percent and provided cash guidance into the second half of 2011.

Amicus/Shire Collaboration Mutual Termination:

Amicus and Shire have reached a mutual termination agreement with respect to their collaboration to jointly develop Amicus' three lead pharmacological chaperone compounds for the treatment of lysosomal storage disorders, effective immediately. As a result of this agreement, Amicus has regained exclusive worldwide rights to develop and commercialize Amigal(TM) (migalastat hydrochloride), Plicera(TM) (afegostat tartrate) and AT2220 (1-deoxynojirimycin HCl) outside of the United States (U.S.) and now owns worldwide rights for these programs. Shire will pay Amicus $5.2 million in the fourth quarter as full and final payment for any amounts that may be due to the Company under the collaboration, and both parties will be relieved of all other future obligations, financial or otherwise.

John F. Crowley, President and CEO of Amicus Therapeutics stated, "Shire has been an excellent partner to work with during the past two years. However, reacquiring the ex-U.S. commercial rights to Amigal furthers our desire to enhance the value of that program for our shareholders. Since Shire and Amicus mutually concluded that Plicera will not move forward to Phase 3 development in Gaucher disease, having global rights to Amigal was of critical import
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in ... surgeries. From vital sign monitoring in ICU to 3D skull printing analysis for ... make real-time clinical decisions with simultaneous access to high precision medical images and ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... of their entire waste to energy process and continue to contribute to the ... Upgrade , Temarry’s Waste to Energy process has been operating at their Mexico ...
(Date:9/2/2015)... Telford, England (PRWEB) , ... September 02, 2015 ... ... for drug discovery and life science research, today unveiled Genedata Screener ® ... platform for all in-vitro screening brings to market a rich set of new ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... California. , Dynal : 400+ employees worldwide, 87 in ... Norway. Brown Deer, Wis. California-based ... ASA , whose U.S. operations are based in Brown ... million. , ,Invitrogen has considered the acquisition since ...
... venture capital performance in the U.S. during 2004. , ,We ... share of this investment as well as how the life science ... detailed look at how the life science industry in the Midwest ... report. , ,Still, I was able to ferret out some ...
... written about the important impact that generic pharmaceutical drugs ... Their rise and growth spurs Big Pharma to invest ... Americans not having any kind of medical health insurance ... medicines from Canada being rapidly shut by U.S. pharmaceutical ...
Cached Biology Technology:Invitrogen to buy Norwegian biotech with operations in Brown Deer 2Midwest VC investment up in 2004, but number of deals down 2Midwest VC investment up in 2004, but number of deals down 3Pharmas will be forced into generic-drug strategy 2Pharmas will be forced into generic-drug strategy 3
(Date:8/28/2015)... , August 28, 2015 ... and Training Market by Assessment Type (Pen & Paper ... Brain Training, Corporate Learning, Academic Research), Vertical and Region ... Assessment and Training Market to grow from USD 2.4 ... at a Compound Annual Growth Rate (CAGR) of 25.6% ...
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... for new antibiotics: A new research published in the July ... http://www.fasebj.org ) explains for the first time how honey kills ... that they add to the honey, called defensin-1, which could ... and to develop new drugs that could combat antibiotic-resistant infections. ...
... WEST LAFAYETTE, Ind. - Fast-food restaurants can supersize French ... to supersize a type of apple. Peter Hirst, a ... in some Gala apple trees causes some apples to grow ... reported in the current issue of the Journal of ...
... A drug used to treat rheumatoid arthritis also reduces ... lab research and preliminary findings from a clinical trial of ... clinical study to refine the drug anakinra,s use as an ... Nancy Rothwell will summarise her team,s latest research into both ...
Cached Biology News:Honey as an antibiotic: Scientists identify a secret ingredient in honey that kills bacteria 2Apples grow larger when cells don't divide, study shows 2New hope for victims of stroke 2
Human LAIR2 Biotinylated Affinity Purified PAb...
... The mycobacteria in ... cells to the injection site which enhances ... Freund's Adjuvant is used for the initial ... the subsequent boosts. Antigens (preferably in saline) ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
Biology Products: